Martin P Ogrodzinski
Overview
Explore the profile of Martin P Ogrodzinski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Broadwater D, Medeiros H, Bates M, Roshanzadeh A, Teoh S, P Ogrodzinski M, et al.
ACS Appl Mater Interfaces
. 2022 Nov;
14(48):53511-53522.
PMID: 36408853
Photodynamic therapy (PDT) has the potential to improve cancer treatment by providing dual selectivity through the use of both photoactive agent and light, with the goal of minimal harmful effects...
2.
Panwalkar P, Tamrazi B, Dang D, Chung C, Sweha S, Natarajan S, et al.
Sci Transl Med
. 2021 Oct;
13(614):eabc0497.
PMID: 34613815
Childhood posterior fossa group A ependymomas (PFAs) have limited treatment options and bear dismal prognoses compared to group B ependymomas (PFBs). PFAs overexpress the oncohistone-like protein EZHIP (enhancer of Zeste...
3.
P Ogrodzinski M, Teoh S, Lunt S
Cancer Res
. 2020 Oct;
81(2):303-314.
PMID: 33115804
Investigating metabolic rewiring in cancer can lead to the discovery of new treatment strategies for breast cancer subtypes that currently lack targeted therapies. In this study, we used MMTV-Myc-driven tumors...
4.
Teoh S, P Ogrodzinski M, Lunt S
Cancer Lett
. 2020 Aug;
492:21-30.
PMID: 32768525
Dysregulated metabolism is a hallmark of cancer that supports tumor growth and metastasis. One understudied aspect of cancer metabolism is altered nucleotide sugar biosynthesis, which drives aberrant cell surface glycosylation...
5.
P Ogrodzinski M, Teoh S, Lunt S
Cell Oncol (Dordr)
. 2020 Jul;
43(6):1117-1127.
PMID: 32691367
Purpose: Breast cancer is a heterogeneous disease with several subtypes that currently do not have targeted therapeutic options. Metabolomics has the potential to uncover novel targeted treatment strategies by identifying...
6.
Yu L, Teoh S, Ensink E, P Ogrodzinski M, Yang C, Vazquez A, et al.
Cancer Metab
. 2020 Jan;
7:13.
PMID: 31893043
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with limited treatment options. Pyruvate kinase, especially the M2 isoform (PKM2), is highly expressed in PDAC cells, but its role in...
7.
Rennhack J, To B, Swiatnicki M, Dulak C, P Ogrodzinski M, Zhang Y, et al.
Nat Commun
. 2019 Jul;
10(1):3261.
PMID: 31332182
Mouse models have an essential role in cancer research, yet little is known about how various models resemble human cancer at a genomic level. Here, we complete whole genome sequencing...
8.
P Ogrodzinski M, Teoh S, Yu L, Broadwater D, Ensink E, Lunt S
Methods Mol Biol
. 2018 Oct;
1862:37-52.
PMID: 30315458
Metabolite extraction from cells cultured in vitro enables the comprehensive measurement of intracellular metabolites. These extracts can be analyzed using techniques such as liquid chromatography-mass spectrometry (LC-MS). This chapter describes...
9.
Teoh S, P Ogrodzinski M, Ross C, Hunter K, Lunt S
Front Oncol
. 2018 Jun;
8:174.
PMID: 29892572
Metastatic breast cancer is currently incurable. It has recently emerged that different metabolic pathways support metastatic breast cancer. To further uncover metabolic pathways enabling breast cancer metastasis, we investigated metabolic...
10.
Hodeib M, P Ogrodzinski M, Vergnes L, Reue K, Karlan B, Lunt S, et al.
Oncotarget
. 2018 Feb;
9(3):4044-4060.
PMID: 29423103
Metformin is a widely used agent for the treatment of diabetes and infertility, however, it has been found to have anti-cancer effects in a variety of malignancies including high grade...